FDA Okays At-Home Starting Dose for Lecanemab in Early AD

The FDA has approved at-home subcutaneous dosing for lecanemab (Leqembi Iqlik), an Alzheimer's antibody, allowing patients to self-administer or have caregivers administer the starting dose—the first time this disease-modifying treatment can be initiated outside clinical settings. This shift from intravenous to subcutaneous administration removes a major access barrier and enables combination therapy models as the field moves beyond single-drug treatment. If you build home health infrastructure, diagnostics, or remote monitoring for neurodegenerative disease, you now have a proven patient population that will receive repeated weekly drug injections at home—and Eisai needs partners to handle the clinical workflows, adherence tracking, and outcome measurement at scale. Combination therapies are coming; whoever owns the patient touchpoint owns the data.